Vera Therapeutics presents positive 72-week data for atacicept in IgA nephropathy. positive

From GlobeNewswire: 2024-05-25 09:40:00

Vera Therapeutics, Inc. announced promising 72-week data from its Phase 2b ORIGIN trial of atacicept in IgA nephropathy (IgAN). Results show stable kidney function and rapid improvements in hematuria compared to placebo. Eagerly awaited 96-week data expected later this year. Participants on atacicept for 72 weeks had stable kidney function and sustained reductions in key markers. Safety profile remained strong with high retention rate. These results support the potential for atacicept to offer long-term disease modification in IgAN. Selected as a best-ranked abstract at ERA24, atacicept shows promise in modifying IgAN.



Read more at GlobeNewswire: Vera Therapeutics Presents 72-week eGFR Stabilization and